FCC Exempts Select Foreign-Made Drones From U.S. Import Ban Until 2026 
EU Orders Elon Musk’s X to Preserve Grok AI Data Amid Probe Into Illegal Content 
Federal Appeals Court Blocks Trump-Era Hospital Drug Rebate Plan 
Lenovo Unveils AI Cloud Gigafactory With NVIDIA and Launches New AI Platform at CES 2026 
Baidu’s AI Chip Unit Kunlunxin Prepares for Hong Kong IPO to Raise Up to $2 Billion 
Aktis Oncology Prices Upsized IPO at $18, Raising $318 Million in Major Biotech Debut 
Discord Confidentially Files for U.S. IPO, Signaling Major Milestone 
GM Takes $6 Billion EV Write-Down as Electric Vehicle Demand Slows in the U.S. 
AustralianSuper Backs BlueScope Steel’s Rejection of $9 Billion Takeover Bid 
SK Hynix Shares Hit Record High as AI Memory Demand Fuels Semiconductor Rally 
Embraer Boosts Aircraft Deliveries in Q4 2025, Signaling Strong Growth Into 2026 
Newmont Goldcorp Expects Lower Q1 2026 Gold Output After Western Australia Bushfire 
China Reviews Meta’s $2 Billion AI Deal With Manus Amid Technology Control Concerns 
AMD Unveils Next-Generation AI and PC Chips at CES, Highlights Major OpenAI Partnership 
UBS Upgrades L’Oréal to Buy, Sees Strong Sales Momentum and 20% Upside 
Rio Tinto–Glencore Merger Talks Spark Investor Debate Over Value, Strategy and Coal Exposure 
Hyundai Motor Shares Surge on Nvidia Partnership Speculation 
SHELTON, Conn., April 05, 2016 -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting kappa opioid receptors, today announced that Dr. Derek Chalmers, President and CEO, will present a company overview at the 15th Annual Needham Healthcare Conference on Tuesday, April 12, 2016, at 10:00 a.m. ET in New York City.
A live webcast of the presentation can be accessed under “Events and Presentations” in the News & Investors section of the Company’s website at www.CaraTherapeutics.com. An archived webcast recording will be available on the Cara website for approximately 30 days.
About Cara Therapeutics
Cara Therapeutics is a clinical-stage biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting kappa opioid receptors. Cara is developing a novel and proprietary class of product candidates that target the body's peripheral nervous system and have demonstrated efficacy in patients with moderate-to-severe pain without inducing many of the undesirable side effects typically associated with currently available pain therapeutics.
INVESTOR CONTACT: Jesse Baumgartner Stern Investor Relations, Inc. 212-362-1200 [email protected] MEDIA CONTACT: Annie Starr 6 Degrees 973-415-8838 [email protected]
